Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03525405 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03525405 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 8 participants.
The verdict
NCT03525405, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase I, single-center, open-label, single-sequence, study evaluating the absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a mixture 14C-radiolabeled and unlabeled material.
Interventions
- DRUG napabucasin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2018-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03525405
The ClinicalTrials.gov registry entry for NCT03525405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which napabucasin is the first listed.
NCT03525405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03525405 about?
NCT03525405 is a clinical study titled "A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects". This is a Phase I, single-center, open-label, single-sequence, study evaluating the absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a mixture 14C-radiolabeled and unlabeled material.
What is the current status of trial NCT03525405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-05-18. Estimated completion is 2018-06-02.
What interventions are being tested in trial NCT03525405?
The interventions under investigation include: napabucasin (DRUG).
Who is sponsoring clinical trial NCT03525405?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.